The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin

Not Applicable

Recruiting

• Conditions: Sensitive Skin
• Interventions: Drug: bFGF; Drug: Bovine Basic Gel

• Registration Number: NCT06516939
• Lead Sponsor: Shanghai Dermatology Hospital

Brief Summary

The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-10
• Status Verified: 2024-07
• Primary Completion: 2024-07-18
• Study Completion: 2024-07-18
• Study First Submitted: 2024-07-18
• Study First Submitted QC: 2024-07-23
• Last Update Submitted: 2024-07-23
• Study First Posted: 2024-07-24
• Last Update Posted: 2024-07-24

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

1. Sensitive skin with a diagnosis of persistent erythema and a lactate irritation test score of 2-3
2. No related skin care products including bovine alkaline fibroblast growth factor were used within 1 month before participating in the experiment, and photoelectric treatment measures were not carried out
3. Physical sunscreen should be strict during enrollment

Exclusion Criteria

1. Children
2. Have serious heart, liver, kidney, and blood system diseases, and severe immunocompromise
3. Patients with mental illness or cancer
4. Those who have received glucocorticoids, calcineurin inhibitors, topical small molecule drugs, antibiotics or tretinoin within 3 months
5. Those who are allergic to basic fibroblast growth factor gel and its components
6. Acute dermatitis of the face and perifolliculitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
The Application of Bovine Basic Fibroblast Growth Factor Gel	bFGF	-
Bovine Basic Gel	Bovine Basic Gel	-

Primary Outcome Measures

Name	Time	Method
erythema index	0、1、2、4 week	The change rate in lesion clearance of face at 1 month after treatment will be measured as the primary outcome

Trial Locations

Locations (1)

Shanghai Skin Disease Hospital; 🇨🇳 Shanghai, China